Published in Mol Immunol on June 28, 2013
Atypical hemolytic uremic syndrome. Semin Nephrol (2013) 1.56
An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol (2015) 1.42
Hemolytic uremic syndrome. Semin Immunopathol (2014) 1.12
Rare genetic variants in the CFI gene are associated with advanced age-related macular degeneration and commonly result in reduced serum factor I levels. Hum Mol Genet (2015) 0.95
Complement and cytokine response in acute Thrombotic Thrombocytopenic Purpura. Br J Haematol (2013) 0.87
Spectrum and management of complement immunodeficiencies (excluding hereditary angioedema) across Europe. J Clin Immunol (2015) 0.85
Success of eculizumab in the treatment of atypical hemolytic uremic syndrome. Pediatr Nephrol (2014) 0.82
Management of hemolytic uremic syndrome. F1000Prime Rep (2014) 0.82
Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan. Clin Exp Nephrol (2015) 0.81
Eculizumab in atypical haemolytic uraemic syndrome with severe cardiac and neurological involvement. Pediatr Nephrol (2013) 0.81
Atypical haemolytic uraemic syndrome associated with a CD46 mutation triggered by Shigella flexneri. Clin Kidney J (2014) 0.80
Complement activation patterns in atypical haemolytic uraemic syndrome during acute phase and in remission. Clin Exp Immunol (2015) 0.80
Plasma resistant atypical hemolytic uremic syndrome associated with a CFH mutation treated with eculizumab: a case report. J Med Case Rep (2015) 0.79
Complement modulation of T cell immune responses during homeostasis and disease. J Leukoc Biol (2014) 0.79
Kidney disease in children: latest advances and remaining challenges. Nat Rev Nephrol (2016) 0.78
Autoantibodies to CD59, CD55, CD46 or CD35 are not associated with atypical haemolytic uraemic syndrome (aHUS). Mol Immunol (2014) 0.77
PEGylated Artificial Antibodies: Plasmonic Biosensors with Improved Selectivity. ACS Appl Mater Interfaces (2016) 0.77
The relative merits of therapies being developed to tackle inappropriate ('self'-directed) complement activation. Auto Immun Highlights (2016) 0.75
Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders. Clin Exp Immunol (2016) 0.75
Consequences of hemolytic uremic syndrome among hemodialysis patients. J Nephrol (2014) 0.75
Hemolytic uremic syndrome: toxins, vessels, and inflammation. Front Med (Lausanne) (2014) 0.75
Complements Spurned: Our Experience with Atypical Hemolytic Uremic Syndrome. Indian J Crit Care Med (2017) 0.75
A Case Report and Literature Review of Eculizumab Withdrawal in Atypical Hemolytic-Uremic Syndrome. Am J Case Rep (2016) 0.75
Rare genetic variant in the CFB gene presenting as atypical hemolytic uremic syndrome and immune complex diffuse membranoproliferative glomerulonephritis, with crescents, successfully treated with eculizumab. Pediatr Nephrol (2017) 0.75
Complement: a key system for immune surveillance and homeostasis. Nat Immunol (2010) 10.37
Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med (2013) 7.51
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med (2006) 6.90
Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood (2006) 4.51
Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int (1998) 4.03
Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol (2010) 3.82
Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci U S A (2006) 3.80
Atypical hemolytic uremic syndrome. Orphanet J Rare Dis (2011) 3.35
Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood (2008) 3.10
Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol (2007) 3.04
Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med (2009) 3.01
Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol (2004) 2.97
Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition. Am J Hum Genet (2001) 2.92
Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet (2013) 2.91
Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. J Am Soc Nephrol (2006) 2.88
A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int (2006) 2.85
Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol (2007) 2.81
Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med (2009) 2.80
Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci U S A (2003) 2.79
Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome. Am J Hum Genet (2001) 2.75
Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet (2003) 2.71
Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature (2011) 2.64
Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol (2012) 2.62
The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. J Am Soc Nephrol (2001) 2.56
Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J Exp Med (2007) 2.55
Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol (2010) 2.51
Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol (2013) 2.47
Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J Am Soc Nephrol (2004) 2.46
Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat (2010) 2.44
Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. Blood (2009) 2.33
Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol (2008) 2.30
T-cell regulation: with complements from innate immunity. Nat Rev Immunol (2006) 2.27
Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. J Am Soc Nephrol (2005) 2.23
Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol (2010) 2.13
Atypical haemolytic uraemic syndrome associated with a hybrid complement gene. PLoS Med (2006) 2.07
Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum Mol Genet (2005) 2.06
Y402H polymorphism of complement factor H affects binding affinity to C-reactive protein. J Immunol (2007) 2.00
Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation. Blood (2008) 1.95
DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN. J Am Soc Nephrol (2012) 1.93
Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countries. J Med Genet (2003) 1.92
A new map of glycosaminoglycan and C3b binding sites on factor H. J Immunol (2008) 1.89
The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region. J Exp Med (1991) 1.88
Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. Mol Immunol (2006) 1.82
Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. N Engl J Med (2010) 1.80
Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. J Exp Med (1993) 1.73
The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome. J Immunol (2009) 1.70
Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome. Blood (2007) 1.70
Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol (2009) 1.70
Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol (1996) 1.67
Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. Br J Haematol (2009) 1.65
Genetics and complement in atypical HUS. Pediatr Nephrol (2010) 1.64
Complement factor H variants I890 and L1007 while commonly associated with atypical hemolytic uremic syndrome are polymorphisms with no functional significance. Kidney Int (2011) 1.64
Insights into hemolytic uremic syndrome: segregation of three independent predisposition factors in a large, multiple affected pedigree. Mol Immunol (2006) 1.64
The alternative complement pathway revisited. J Cell Mol Med (2008) 1.62
Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant (2012) 1.60
The development of atypical haemolytic-uraemic syndrome is influenced by susceptibility factors in factor H and membrane cofactor protein: evidence from two independent cohorts. J Med Genet (2005) 1.59
Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol (2013) 1.59
Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome. Kidney Int (2009) 1.55
Complement regulatory genes and hemolytic uremic syndromes. Annu Rev Med (2008) 1.55
The factor H variant associated with age-related macular degeneration (His-384) and the non-disease-associated form bind differentially to C-reactive protein, fibromodulin, DNA, and necrotic cells. J Biol Chem (2007) 1.51
De novo gene conversion in the RCA gene cluster (1q32) causes mutations in complement factor H associated with atypical hemolytic uremic syndrome. Hum Mutat (2006) 1.46
Pathology after eculizumab in dense deposit disease and C3 GN. J Am Soc Nephrol (2012) 1.43
Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. Mol Immunol (2007) 1.42
Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. Clin J Am Soc Nephrol (2005) 1.40
Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation. Am J Kidney Dis (2009) 1.39
An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia (2013) 1.37
New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol (2010) 1.36
Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant (2013) 1.31
Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics. Pediatr Nephrol (2012) 1.30
Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol (2011) 1.29
Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation. Pediatr Nephrol (2010) 1.28
A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. Blood (2012) 1.28
Regulation of alternative pathway complement activation by glycosaminoglycans: specificity of the polyanion binding site on factor H. Biochem Biophys Res Commun (1994) 1.26
Genetic disorders in complement (regulating) genes in patients with atypical haemolytic uraemic syndrome (aHUS). Nephrol Dial Transplant (2010) 1.24
New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab. Semin Thromb Hemost (2010) 1.24
Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome. Pediatr Nephrol (2010) 1.20
Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome. Pediatr Nephrol (2011) 1.20
The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab. Br J Haematol (2010) 1.20
Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation. Transplantation (2010) 1.20
Complement factor H binds to denatured rather than to native pentameric C-reactive protein. J Biol Chem (2008) 1.15
Disease-associated N-terminal complement factor H mutations perturb cofactor and decay-accelerating activities. J Biol Chem (2011) 1.15
A mutation in factor I that is associated with atypical hemolytic uremic syndrome does not affect the function of factor I in complement regulation. Mol Immunol (2006) 1.15
Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol (2012) 1.14
Does complement factor B have a role in the pathogenesis of atypical HUS? Mol Immunol (2005) 1.13
Eculizumab: safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome: case report. Transplant Proc (2010) 1.11
Analysis of genetic and predisposing factors in Japanese patients with atypical hemolytic uremic syndrome. Mol Immunol (2013) 1.10
A novel hybrid CFH/CFHR3 gene generated by a microhomology-mediated deletion in familial atypical hemolytic uremic syndrome. Blood (2011) 1.09
Hemolytic uremic syndrome recurrence after renal transplantation. Pediatr Transplant (2008) 1.08
A large family with a gain-of-function mutation of complement C3 predisposing to atypical hemolytic uremic syndrome, microhematuria, hypertension and chronic renal failure. Clin J Am Soc Nephrol (2009) 1.07
Common genetic variants in complement genes other than CFH, CD46 and the CFHRs are not associated with aHUS. Mol Immunol (2011) 1.06
Tissue-specific host recognition by complement factor H is mediated by differential activities of its glycosaminoglycan-binding regions. J Immunol (2013) 1.06
Phenotypic expression of factor H mutations in patients with atypical hemolytic uremic syndrome. Kidney Int (2006) 1.06
A novel non-synonymous polymorphism (p.Arg240His) in C4b-binding protein is associated with atypical hemolytic uremic syndrome and leads to impaired alternative pathway cofactor activity. J Immunol (2008) 1.03
Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH/CFHR1 hybrid protein. Am J Transplant (2012) 1.01
A novel mutation in the complement factor B gene (CFB) and atypical hemolytic uremic syndrome. Pediatr Nephrol (2010) 1.00
Paroxysmal nocturnal hemoglobinuria and eculizumab. Haematologica (2010) 1.00
Eculizumab in the treatment of atypical hemolytic uremic syndrome in infants. Am J Kidney Dis (2011) 1.00
Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood (2006) 4.51
Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. J Am Soc Nephrol (2006) 2.88
Online alcohol interventions: a systematic review. J Med Internet Res (2010) 2.37
C-terminal truncations in human 3'-5' DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy. Nat Genet (2007) 2.35
Structural basis for engagement by complement factor H of C3b on a self surface. Nat Struct Mol Biol (2011) 2.32
A new map of glycosaminoglycan and C3b binding sites on factor H. J Immunol (2008) 1.89
Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. Mol Immunol (2006) 1.82
Rare variants in CFI, C3 and C9 are associated with high risk of advanced age-related macular degeneration. Nat Genet (2013) 1.77
The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome. J Immunol (2009) 1.70
Plasma therapy in atypical haemolytic uremic syndrome: lessons from a family with a factor H mutation. Pediatr Nephrol (2008) 1.68
Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. Br J Haematol (2009) 1.65
Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. PLoS Med (2011) 1.52
Integrated versus non-integrated management and care for clients with co-occurring mental health and substance use disorders: a qualitative systematic review of randomised controlled trials. Soc Sci Med (2005) 1.39
Being stoned: a review of self-reported cannabis effects. Drug Alcohol Rev (2003) 1.30
Cannabis use and misuse prevalence among people with psychosis. Br J Psychiatry (2005) 1.24
Structure of the N-terminal region of complement factor H and conformational implications of disease-linked sequence variations. J Biol Chem (2008) 1.16
Disease-associated N-terminal complement factor H mutations perturb cofactor and decay-accelerating activities. J Biol Chem (2011) 1.15
Psychometric validation of the Growth and Empowerment Measure (GEM) applied with Indigenous Australians. Aust N Z J Psychiatry (2010) 1.10
A novel hybrid CFH/CFHR3 gene generated by a microhomology-mediated deletion in familial atypical hemolytic uremic syndrome. Blood (2011) 1.09
Advances in understanding of pathogenesis of aHUS and HELLP. Br J Haematol (2008) 1.05
A novel non-synonymous polymorphism (p.Arg240His) in C4b-binding protein is associated with atypical hemolytic uremic syndrome and leads to impaired alternative pathway cofactor activity. J Immunol (2008) 1.03
Collaborative recovery: an integrative model for working with individuals who experience chronic and recurring mental illness. Australas Psychiatry (2005) 1.02
Impulsivity and positive psychotic symptoms influence hostility in methamphetamine users. Addict Behav (2008) 0.99
Thrombotic microangiopathy associated with interferon beta. N Engl J Med (2014) 0.97
Effect of mobile phone-based psychotherapy in suicide prevention: a randomized controlled trial in Sri Lanka. J Telemed Telecare (2012) 0.94
Hemolytic uremic syndrome: an example of insufficient complement regulation on self-tissue. Ann N Y Acad Sci (2005) 0.94
Risk factors for restless legs syndrome in dialysis patients. Nephron Clin Pract (2005) 0.93
Reasons for substance use among people with mental disorders. Addict Behav (2011) 0.93
Content and functionality of alcohol and other drug websites: results of an online survey. J Med Internet Res (2010) 0.91
Images of desire: cognitive models of craving. Memory (2004) 0.91
Triggering of atypical hemolytic uremic syndrome by influenza A (H1N1). Ren Fail (2010) 0.90
Memory suppression in PTSD treatment? Science (2007) 0.90
Determining the population frequency of the CFHR3/CFHR1 deletion at 1q32. PLoS One (2013) 0.90
Factor H autoantibodies in membranoproliferative glomerulonephritis. Mol Immunol (2012) 0.89
Visuospatial tasks suppress craving for cigarettes. Behav Res Ther (2010) 0.88
Complement factor h autoantibodies and age-related macular degeneration. Invest Ophthalmol Vis Sci (2010) 0.87
Listening, sharing understanding and facilitating consumer, family and community empowerment through a priority driven partnership in Far North Queensland. Australas Psychiatry (2009) 0.86
Plasma therapy for atypical haemolytic uraemic syndrome associated with heterozygous factor H mutations. Pediatr Nephrol (2011) 0.84
Structural and functional characterization of the product of disease-related factor H gene conversion. Biochemistry (2012) 0.83
Acute respiratory infection in a renal transplant recipient. Nephrol Dial Transplant (2005) 0.82
Study protocol: Screening and Treatment of Alcohol-Related Trauma (START) - a randomised controlled trial. BMC Health Serv Res (2012) 0.82
TGFβ and CCN2/CTGF mediate actin related gene expression by differential E2F1/CREB activation. BMC Genomics (2013) 0.82
Pulling the trigger in atypical hemolytic uremic syndrome: the role of pregnancy. J Am Soc Nephrol (2010) 0.81
Integrating treatment for mental and physical disorders and substance misuse in Indigenous primary care settings. Australas Psychiatry (2011) 0.81
The influence of pre-operative electrocardiographic abnormalities and cardiovascular risk factors on patient and graft survival following renal transplantation. J Nephrol (2002) 0.80
Challenges faced by general practitioners and allied mental health services in providing mental health services in rural Queensland. Aust J Rural Health (2007) 0.79
Pathogenesis of thrombotic microangiopathy: insights from animal models. Nephron Exp Nephrol (2009) 0.79
Crystallographic determination of the disease-associated T1184R variant of complement regulator factor H. Acta Crystallogr D Biol Crystallogr (2011) 0.78
A randomized controlled trial of a correspondence-based intervention for carers of relatives with psychosis. Clin Psychol Psychother (2013) 0.78
Emotional and behavioral reaction to intrusive thoughts. Assessment (2009) 0.76
Changing strategies for organ transplantation in atypical haemolytic uraemic syndrome: a tertiary case series. Pediatr Transplant (2013) 0.76
Baby Steps - An Online Program Promoting the Well-Being of New Mothers and Fathers: A Study Protocol. JMIR Res Protoc (2016) 0.75
David L. Rosenhan (1929-2012). Am Psychol (2013) 0.75
Mental health issues and resources in rural and regional communities: an exploration of perceptions of service providers. Aust J Rural Health (2007) 0.75
Should mental health issues be addressed in primary care, and can it be done? Views of rural general practitioners in Queensland. Australas Psychiatry (2007) 0.75
Exploring functional concerns in help-seeking youth: a qualitative study. Early Interv Psychiatry (2013) 0.75
Carers' hope, wellbeing and attitudes regarding recovery. Community Ment Health J (2012) 0.75